{"id":36563,"date":"2020-02-20T06:43:34","date_gmt":"2020-02-20T06:43:34","guid":{"rendered":"https:\/\/www.similima.com\/?p=36563"},"modified":"2024-08-02T00:31:26","modified_gmt":"2024-08-02T00:31:26","slug":"report-on-4th-international-conference-of-integrative-oncology-at-cochin-feb-2020","status":"publish","type":"post","link":"https:\/\/www.homeobook.com\/report-on-4th-international-conference-of-integrative-oncology-at-cochin-feb-2020\/","title":{"rendered":"Report on 4th international conference of integrative oncology Cochin"},"content":{"rendered":"

 <\/p>\n

Report on 4th international conference of integrative oncology at Cochin Feb 2020<\/p>\n

Conventional Oncology Care Versus AYUSH modalities.<\/strong><\/p>\n

AYUSH streams can be used as \u2013<\/strong><\/p>\n

    \n
  1. Fields of integration (either after treatment or along with )eg- oral thrush, radiation mucositis, alopecia, discoloration, fibrosis, atrophy)<\/li>\n
  2. Complementary therapies (for physiological balance. Eg- Cancer related fatigue CRF)<\/li>\n
  3. Alternative therapies. (either when benefits of \u00a0S\/P- CT\/RT is not beneficial)<\/li>\n
  4. Adjuvant and neo adjuvant therapies.(to regain blood count, or where low count contra indicates therapies<\/li>\n
  5. Rejuvenating therapies (stabilizing homeostatsis after treatment, regain of papillae in tongue to regain taste sensation)<\/li>\n
  6. Optimizing physiological balances.(aplastic anemia, electroloyte imbalances, protein loss, weight loss)<\/li>\n
  7. Addressing Post treatment sequelae.(emotional, psychological, mood changes, panic attacks, fear of recurrence, control of intervening infections)<\/li>\n
  8. Metastatic carcinomas.( brain and bone involvement, lung nodules in pre existing primaries where more chemo radiation is not possible)<\/li>\n
  9. Aged malignancies where treatment is optional.( benefits and cost of treatment outweighs status of the patient especially where multi drug regimen is planned, or where targeted therapies or immune therapy is planned.<\/li>\n
  10. Levels of malignancy where immunotherapy is indicated but nor feasible.<\/li>\n
  11. Triple negative and double negative breast cancers.(where trastuzumab or tamoxifine is less sensitive or not beneficial)<\/li>\n
  12. Hepato biliary malignancies with co morbidities.(high PT-INR, history of CLD, where TACE \/ RFA is not possible)<\/li>\n
  13. Pancreatic malignancies.(especially post whipples surgery, with liver metastasis, with obstructive jaundice where PTBD stenting is not possible)<\/li>\n
  14. Stage \u00be lung malignancies (especially with low performance status ,EGFR \u2013ve, or with low body weight or with dissemination where CT or RT is not feasible)<\/li>\n
  15. Relapse in hematological malignancies.(especially in childhood malignancies, where BMT is advised but with bizarre results)<\/li>\n
  16. Tumor markers upsurge after conventional treatments.(CA-125, CEA, CA19.9, PSA, AFP)<\/li>\n
  17. Recurrence in post surgical cases.(Glioma, lymphomas, for neurological focal deficits, CA colon, Ca Bladder where repeated TURBT is not giving relief.<\/li>\n
  18. Lymph node metastasis.( continuous fever)<\/li>\n
  19. Esophageal malignancies where low EF contra indicates chemo radiation.<\/li>\n
  20. CA\u00a0stomach – inoperability with cachexia , post surgical vomiting, post surgical flatus<\/li>\n
  21. Urinary bladder malignancies where repeated TURBT is not giving stability<\/li>\n
  22. Cervical cancer where chemo radiation is risky due to advanced stages or low physiological status.<\/li>\n<\/ol>\n

    Therapeutic goals<\/strong><\/p>\n

      \n
    1. Primary cyto-reduction<\/li>\n
    2. Control of intervening infections<\/li>\n
    3. Metastatic foci reversal<\/li>\n
    4. Lymph node regression<\/li>\n
    5. Quality of life<\/li>\n
    6. Enhancement of survival rate.<\/li>\n
    7. Optimizing the organism fit for essential interventions like chemo radiation or surgical.<\/li>\n
    8. Physiological equilibrium.<\/li>\n
    9. Reduction of the pace of Metastasis.<\/li>\n<\/ol>\n

      Day 1 : \u00a08th Feb 2020 – Forenoon<\/p>\n

      Inaugural Session
      \nChief Guest
      \nDr Michael Dixon –\u00a0 <\/span>Chair, College of Medicine & Integrative Health U.K., Personal Physician to Prince Charles, Visiting Professor, University of Westminister & University College, London<\/p>\n

      Guests of Honor
      \nDr Abdu Samad Samadani – Former MLA, MP
      \nShri Pradee Narang – Chairman, Shri Aurobindo Society
      \nShri Reji Abraham,\u00a0 <\/span>Managing Director, Aban Group\u00a0
      \n<\/span>Shri Madhavan Nambiar IAS – Former Civil Aviation Secretary, GoI
      \nDr Issac Mathai – Co-Founder, Dr Mathai’s International Holistic Health Centre
      \nDr Eswaradas – Chairman, GHF<\/p>\n

      Felicitations
      \nDr Velavan – Radiation Oncologist, Director – Erode & Bangalore Cancer Center.
      \nDr KM Madhu – Kottakkal Arya Vaidya Sala
      \nDr Jayesh V Sanghavi – Vice Chairman GHF
      \nDr Sandeep Roy – Chairman, Organizing Committee
      \nDr Piyush Josh – Secretary General, HMAI
      \nDr T K Harindranath – President, IHMA<\/p>\n

      Vote Of Thanks
      \nDr Sreevals Menon – Managing Trustee, GHF<\/p>\n

      Inaugural Messages from Dr Michael Dixon U.K. & others.
      \nInaugurating the event, Dr Michael Dixon called upon integration\u00a0in action of various medical streams while combating diseases. He said that integration in action has become imperative because of increased prevalence of obesity, diabetes and other long-term diseases, depression, stress and cancer. Dr Dixon pointed out that anti-microbial resistance over prescription of opiates and over prescription of conventional medicine have compounded the situation.<\/p>\n

      He pointed out that even as these issues persist back home in UK, NHS England banned herbal and homeopathic medicine while Royal College of General Practitioners asked GPs not to offer Homeopathy and National Institute for Clinical Excellence changed guidelines on palliative care and back pain.<\/p>\n

      He, however, said the good news is that at last AYUSH has arrived in UK with College of Medicine and Integrated Health taking the lead and it is also forming an Integrated Medical Alliance apart from organizing a yoga conference.<\/p>\n

      He said that integration of medical systems was of paramount importance in oncology for prevention, treatment, treating side effects of conventional medicine and preventing recurrence. He stressed up on the need for art interventions like reading, singing and dancing in groups in order to bust the stress of the patients apart from going for a robust regime of exercises.<\/p>\n

      Dr Issac Mathai vouched for the need of Integration while Shri Samadani highlighted on the impact of AYUSH in the current times.<\/p>\n

      Those who addressed the inaugural function included Dr Jayesh Sanghavi, Vice Chairman GHF;\u00a0 Dr T K Harindranath, President, Indian Homeopathic Medical Association; Dr Piyush Joshi, Secretary-General, Homeopathic Medical Association of India, Mr Reji Abraham, Managing Director, Aban Group; Abdu Samad Samadani, Patron GHF; Dr Eswaradas, Chairman, GHF; Dr Pradeep Narang, Patron-GHF and Chairman, Sri Aurobindo Society, Bangalore; Dr Issac Mathai, Soukya Holistic Clinic; Dr Velavan, Radiation Oncologist, Erode Cancer Centre;\u00a0 Dr Sandeep Roy, Chairman, Organizing committee ICIO 2020; Dr Madhavan Nambiar IAS (retd.), Patron GHF and Dr Sreevals G Menon, Managing Trustee, GHF.<\/p>\n

      Panel 1
      \nIntegration in current oncology practices with AYUSH streams – challenges and outcomes
      \nDr Sreevals Menon, Managing trustee – GHF coordinated the session<\/b><\/p>\n

      Speakers
      \nDr.Michael dixon (U.K) – –\u00a0 <\/span>Chair, College of Medicine & Integrative Health U.K., Personal Physician to Prince Charles, Visiting Professor, University of Westminister & University College, London
      \nDr Nilanjana basu – Researcher at Amity Institute Of Molecular Medicine & Stem Cell Research in Amity University
      \nDr Iaonnis papastoriou – Medical Geneticist, Researcher (Greece)
      \nDr Vinu krishnan – Heads the only Public Sector Cancer Hospital under Homeopathy in Kerala
      \nDr K.M Madhu – Kottakkal Arya Vaidya Sala
      \nDr Ravi doctor – Integrative Oncologist – Mumbai<\/p>\n

      Panelists
      \nDr Issac Mathai –\u00a0Co-Founder, Dr Mathai’s International Holistic Health Centre
      \nDr Prasanth parameswaran – Medical Onclogist, MVR Cancer Centre – Kannur – Kerala
      \nDr Radha Das – Former Advisor – Homeopathy, AYUSH Ministry, GoI<\/p>\n

      Transactions
      \nDr Dixon enunciated regarding the idea of\u00a0 integration amongst health providers and systems for the benefits and prognosis for cases in general\u00a0 and oncology\u00a0 in particular.\u00a0He elaborated on the various stages how it could be achieved efficiently.<\/p>\n

      Dr Nilanjana Basu highlighted the cytotoxic effects on breast cancer cells by homeopathic medicine arnica montana. It was phytoprotective to the normal breast cells. Her work as Researcher at Amity Institute Of Molecular Medicine & Stem Cell Research in Amity University was demonstrated.<\/p>\n

      Dr Papastoriou envisaged a therapeutic plan of integration where conventional\u00a0 medicine\u00a0 <\/span>is less sensitive and not feasible.<\/p>\n

      Dr K.M Madhu spoke about\u00a0 the relevance of\u00a0 a multi disciplinary approach\u00a0 in oncology\u00a0 for comprehensive\u00a0care in the light of his experience in the ace Ayurvedic institution in south india which has set a branchmark.<\/p>\n

      Dr Ravi\u00a0doctor\u00a0exemplified the usage of European mistletoe along with homeopathic\u00a0 medicine in quality of life and extended\u00a0 survival in cancer patients of 3rd and 4th stage.<\/p>\n

      Dr.Vinu krishnan from\u00a0 govt Homoeopathic cancer center at wandoor, kerala, India, the unique\u00a0 exclusive\u00a0 cancer\u00a0 management center in homeopathy under\u00a0 public\u00a0 sector\u00a0 figured the enhancement\u00a0 of survival rate and stability of\u00a0 performance\u00a0 status in stage 3 and stage 4 lung cancers\u00a0 using\u00a0 Homoeopathic intervention in a sample size of 60 cases. He drew an analysis and observations of sixty cases of stage 3 and stage 4 lung cancers using Homoeopathic\u00a0 interventions.<\/p>\n

      Dr Issac Mathai appreciated the papers and the effort taken in establishing the idea of integration. He explained the integration happening at his own Holistic Hospital for th past decades effectively for various chronic diseases including cancer.<\/p>\n

      Dr Prashanth Parameshwaran stressed on the need of primary prevention in cancer. He vouched to focus on prevention since it is as important as prevention in cancer. He explained primary prevention as well as secondary prevention. He gave examples of tobacco usage as one of most important cause of cancer which can be prevented by creating awareness in population. It can be achieved through all systems of treatment.<\/p>\n

      Dr Radha said the paper from dr Vinu showed how best in a Govt set up the suffering of cancer patients can be reduced by Homeopathic medicines. The treatment of multi-factorial diseases like cancer needs attention in nutrition, psychologocial interventions, lifestyle modifications along with medical treatment.<\/p>\n

      Session coordinator Dr Sreevals G Menon made a successful\u00a0 derivation from the talks and spotted\u00a0 the challenges and outcomes in\u00a0 integrating current oncology practices with\u00a0 AYUSH<\/p>\n

      8th Feb 2020 – Postnoon<\/p>\n

      Psycho-Oncology \/ IPOS Session (Special Panel)
      \nDr Veenavani Nalleppalli coordinated the session<\/b><\/p>\n

      The Psycho Oncology session was a collective work of Gobal Homoeopathy Foundation (GHF), ICIO and International Psycho Oncology Society (IPOS).The session was coordinated by Dr.Veenavani Nallepalli<\/p>\n

      Speakers<\/p>\n